320 completed, 105 unknown, 78 recruiting, 37 active not recruiting. 190 Phase 4, 160 Phase 3, 126 Phase 2, 80 Phase 1, 48 Not applicable.
Follow dapagliflozin: new trials by email Literature Review of dapagliflozin trials Research Report on dapagliflozin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Dapagliflozin 10mg, Dapagliflozin Placebo - Nonobstructive Hypertrophic Cardiomyopathy | Phase 4 | Not yet recruiting | Yonsei University | 440 | 2027-01-02 | 2026-10-27 |
| dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin - Type 1 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | Not yet recruiting | University Medical Center Groningen | 36 | 2027-01-01 | 2026-10-20 |
| Validation & Intervention Testing for Aging, Longevity and Healthspan Dapagliflozin 10Mg Oral Tablet, Semaglutide oral, Placebo - Aging, Functional Decline | Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 1200 | 2027-01-01 | 2026-11-06 |
| Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI Empagliflozin (SGLT2i), dapagliflozin, Standard medical treatment - No Reflow Phenomenon, Reperfusion Injuries, Myocardial | Phase 2 | Not yet recruiting | Al-Azhar University | 100 | 2027-01-01 | 2026-10-27 |
| Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis Dapagliflozin, Empagliflozin, Methotrexate - Rheumatoid Arthritis (RA) | Phase 2 | Not yet recruiting | Al-Azhar University | 90 | 2026-12-01 | 2026-10-08 |
| Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis Dapagliflozin (DAPA), Spironolactone (drug), Spironolactone + Dapagliflozin - Aortic Stenosis | Phase 2 | Not yet recruiting | University College, London | 445 | 2026-12-01 | 2026-09-11 |
| Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes Acetazolamide 62.5 mg, Acetazolamide 125 mg, Acetazolamide 250 mg - T2D | Phase 2 | Not yet recruiting | University Health Network, Toronto | 20 | 2026-12-01 | 2026-10-29 |
| Dapagliflozin for Long COVID Syndrome Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome | Phase 3 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 192 | 2026-12-01 | 2026-10-30 |
| iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) N0892, Januvia® + Glifage XR® + Placebo, Forxiga® + Glifage XR® + Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-11-30 | 2025-12-18 | |
| Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2026-11-01 | 2026-06-22 |
| Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis Placebo, Dapagliflozin (10mg Tab) - Rheumatoid Arthritis (RA | Phase 1 / Phase 2 | Not yet recruiting | Tanta University | 100 | 2026-10-30 | 2026-10-28 |
| Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis Rezdiffra, Resmetirom, ACTOS/pioglitazone - MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 4 | Recruiting | Madrigal Pharmaceuticals, Inc. | 150 | 2026-10-07 | 2026-11-16 |
| Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab) - MAFLD in Prediabetes and Diabetes | Phase 4 | Not yet recruiting | Sherihan AboElyazed Mohamed Khalil | 66 | 2026-10-01 | 2026-10-23 |
| Metformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD Metformin + Dapagliflozin, Metformin - Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease | Not applicable | Not yet recruiting | The 95th Hospital of Putian,Putian, Fujian, China | 84 | 2026-10-01 | 2026-08-21 |
| Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome Metformin, Dapagliflozin (10mg Tab) - Poly Cystic Ovary Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 60 | 2026-09-10 | 2026-09-09 |
| A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) Balcinrenone/dapagliflozin, Dapagliflozin, Placebo matching Dapagliflozin - Renal Insufficiency, Chronic | Phase 3 | Recruiting | AstraZeneca | 2800 | 2026-09-01 | 2026-09-24 |
| Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes Dapagliflozin (10mg Tab) - Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Not yet recruiting | Seug yun Yoon, MD | 37 | 2026-09-01 | 2026-04-08 |
| Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial Dapagliflozin, Metformin, Common Lifestyle Program - Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain | Phase 4 | Not yet recruiting | Sultan Qaboos University | 110 | 2026-09-01 | 2026-06-10 |
| SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial SGLT2i, Placebo - Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors | Phase 2 | Not yet recruiting | Odense University Hospital | 184 | 2026-09-01 | 2026-07-02 |
| aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA) Dapagliflozin (10mg Tab), Placebo ( FE) - Angina With Non-Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction (CMD) | Phase 2 | Not yet recruiting | The Christ Hospital | 120 | 2026-09-01 | 2026-08-03 |
Showing 20 of 614. Sign in to see all of them.
Diabetes Mellitus, Type 2 (226) · Diabetes Mellitus (60) · Heart Failure (58) · Renal Insufficiency, Chronic (45) · Diabetes Mellitus, Type 1 (25) · Hypertension (14) · Obesity (12) · Prediabetic State (12) · Breast Neoplasms (11) · Insulin Resistance (11) · Myocardial Infarction (11) · Atrial Fibrillation (10) · Coronary Artery Disease (10) · Diabetic Nephropathies (10) · Hyperglycemia (10)
AstraZeneca (125) · The University of Texas Health Science Center at San Antonio (13) · Mansoura University (10) · Assiut University (9) · LG Chem (8) · Ain Shams University (7) · Tanta University (7) · University of Guadalajara (6) · Washington University School of Medicine (6) · Beni-Suef University (5) · Boryung Pharmaceutical Co., Ltd (5) · Brigham and Women's Hospital (5) · Dong-A ST Co., Ltd. (5) · Medical University of Vienna (5) · The University of Hong Kong (5)
United States (170) · South Korea (68) · China (62) · Egypt (58) · Mexico (56) · Canada (55) · Germany (50) · United Kingdom (45) · Spain (41) · Poland (40) · Brazil (35) · Italy (35) · Sweden (32) · India (31) · Japan (31)
Mikhail Kosiborod, MD (4) · Eugenio Cersosimo, MD,PhD (3) · Ralph A DeFronzo, MD (3) · Ralph DeFronzo, MD (3) · Anna Maria Langkilde (2) · Anna Maria Langkilde, MD (2) · Bassem Zarif, MD (2) · Hiddo J Lambers Heerspink, PhD, PharmD (2) · Jan Eriksson, MD (2) · Moheb Magdy Mouris, MD (2)
PMID 38770818, PMID 26894924, PMID 31535829, PMID 26378978, PMID 32970396, PMID 27461213, PMID 28605608, PMID 31081589, PMID 33368935, PMID 30415602, PMID 32865377, PMID 35403243, PMID 36027570, PMID 40913594, PMID 19114612, PMID 23668478, PMID 25352655, PMID 25425451, PMID 27440829, PMID 29802530, PMID 30756462, PMID 30990260, PMID 31196815, PMID 31364269, PMID 31843945, PMID 32559474, PMID 32691513, PMID 32877652, PMID 32946821, PMID 34447992, PMID 34473343, PMID 34693515, PMID 35241246, PMID 36189985, PMID 36811901, PMID 36881399, PMID 37170711, PMID 37203441, PMID 37210608, PMID 37211977, PMID 37220172, PMID 37227937, PMID 37886880, PMID 38017482, PMID 38059368, PMID 38299639, PMID 38320525, PMID 38334499, PMID 38430085, PMID 39046727
2023 (13), 2014 (9), 2015 (8), 2016 (6), 2017 (5), 2018 (4), 2025 (4), 2019 (3), R01DK024092 (3), R01DK107680 (3), 1OT2HL156812-01 (1), K23DK142042 (1), K23HL150236 (1), KL2TR003016 (1), P30AG044271 (1)